Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10228051rdf:typepubmed:Citationlld:pubmed
pubmed-article:10228051lifeskim:mentionsumls-concept:C0035236lld:lifeskim
pubmed-article:10228051lifeskim:mentionsumls-concept:C0020971lld:lifeskim
pubmed-article:10228051lifeskim:mentionsumls-concept:C0021289lld:lifeskim
pubmed-article:10228051lifeskim:mentionsumls-concept:C1858460lld:lifeskim
pubmed-article:10228051lifeskim:mentionsumls-concept:C0003241lld:lifeskim
pubmed-article:10228051lifeskim:mentionsumls-concept:C1522673lld:lifeskim
pubmed-article:10228051lifeskim:mentionsumls-concept:C0591833lld:lifeskim
pubmed-article:10228051lifeskim:mentionsumls-concept:C1175000lld:lifeskim
pubmed-article:10228051pubmed:issue6lld:pubmed
pubmed-article:10228051pubmed:dateCreated1999-6-21lld:pubmed
pubmed-article:10228051pubmed:abstractTextAlum-adsorbed BBG2Na, a recombinant vaccine derived in part from the respiratory syncytial virus (RSV) subgroup A G protein, induced moderate antibody titers after 1 immunization in 1-week-old mice but conferred complete lung protection upon RSV challenge. The anti-BBG2Na IgG1-IgG2a neonatal isotype profile was suggestive of dominant Th2 responses compared with those in adults. Formulation of BBG2Na with a Th1-driving adjuvant efficiently shifted neonatal responses toward a more balanced and adultlike IgG1-IgG2a profile without compromising its protective efficacy. BBG2Na-induced protective immunity was maintained even after early life immunization in the presence of high titers of maternal antibodies. Under these conditions, the protective efficacy (86%-100%) reflected the high capacity of the nonglycosylated G2Na immunogen to escape inhibition by RSV-A-induced maternal antibodies. Thus, immunization with BBG2Na protected against viral challenge despite neonatal immunologic immaturity and the presence of maternal antibodies, two major obstacles to neonatal RSV vaccine development.lld:pubmed
pubmed-article:10228051pubmed:languageenglld:pubmed
pubmed-article:10228051pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10228051pubmed:citationSubsetAIMlld:pubmed
pubmed-article:10228051pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10228051pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10228051pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10228051pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10228051pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10228051pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10228051pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10228051pubmed:statusMEDLINElld:pubmed
pubmed-article:10228051pubmed:monthJunlld:pubmed
pubmed-article:10228051pubmed:issn0022-1899lld:pubmed
pubmed-article:10228051pubmed:authorpubmed-author:LambertP HPHlld:pubmed
pubmed-article:10228051pubmed:authorpubmed-author:BernerRRlld:pubmed
pubmed-article:10228051pubmed:authorpubmed-author:CórdovaMMlld:pubmed
pubmed-article:10228051pubmed:authorpubmed-author:BonnefoyJ YJYlld:pubmed
pubmed-article:10228051pubmed:authorpubmed-author:PowerU FUFlld:pubmed
pubmed-article:10228051pubmed:authorpubmed-author:NguyenT NTNlld:pubmed
pubmed-article:10228051pubmed:authorpubmed-author:SiegristC ACAlld:pubmed
pubmed-article:10228051pubmed:authorpubmed-author:Plotnicky-Gil...lld:pubmed
pubmed-article:10228051pubmed:issnTypePrintlld:pubmed
pubmed-article:10228051pubmed:volume179lld:pubmed
pubmed-article:10228051pubmed:ownerNLMlld:pubmed
pubmed-article:10228051pubmed:authorsCompleteYlld:pubmed
pubmed-article:10228051pubmed:pagination1326-33lld:pubmed
pubmed-article:10228051pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10228051pubmed:meshHeadingpubmed-meshheading:10228051...lld:pubmed
pubmed-article:10228051pubmed:meshHeadingpubmed-meshheading:10228051...lld:pubmed
pubmed-article:10228051pubmed:meshHeadingpubmed-meshheading:10228051...lld:pubmed
pubmed-article:10228051pubmed:meshHeadingpubmed-meshheading:10228051...lld:pubmed
pubmed-article:10228051pubmed:meshHeadingpubmed-meshheading:10228051...lld:pubmed
pubmed-article:10228051pubmed:meshHeadingpubmed-meshheading:10228051...lld:pubmed
pubmed-article:10228051pubmed:meshHeadingpubmed-meshheading:10228051...lld:pubmed
pubmed-article:10228051pubmed:meshHeadingpubmed-meshheading:10228051...lld:pubmed
pubmed-article:10228051pubmed:meshHeadingpubmed-meshheading:10228051...lld:pubmed
pubmed-article:10228051pubmed:meshHeadingpubmed-meshheading:10228051...lld:pubmed
pubmed-article:10228051pubmed:meshHeadingpubmed-meshheading:10228051...lld:pubmed
pubmed-article:10228051pubmed:meshHeadingpubmed-meshheading:10228051...lld:pubmed
pubmed-article:10228051pubmed:meshHeadingpubmed-meshheading:10228051...lld:pubmed
pubmed-article:10228051pubmed:year1999lld:pubmed
pubmed-article:10228051pubmed:articleTitleProtective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: influence of adjuvants and maternal antibodies.lld:pubmed
pubmed-article:10228051pubmed:affiliationWorld Health Organization Collaborating Center for Neonatal Vaccinology, University of Geneva, 1211 Geneva 4, Switzerland. siegrist@cmu.unige.chlld:pubmed
pubmed-article:10228051pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10228051pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10228051lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10228051lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10228051lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10228051lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10228051lld:pubmed